Krsnaa Diagnostics gets in-principle approval for ₹566 warrant issue
- Krsnaa Diagnostics received in-principle approval from BSE and NSE for issuing 16,21,000 convertible warrants.
- Warrants are issued to the promoter group at an issue price of ₹566 per share on a preferential basis.
- Conversion will result in equity shares with a face value of ₹5 each.
- NSE advised strengthening internal controls to monitor allottee trades and prevent intra-day trading violations.

*this image is generated using AI for illustrative purposes only.
Krsnaa Diagnostics Limited has received in-principle approval from BSE and the National Stock Exchange of India (NSE) for issuing 16,21,000 convertible warrants to its promoter group. The warrants are priced at ₹566 each on a preferential basis.
The approval, granted under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, permits the conversion of these warrants into equity shares with a face value of ₹5 each. The company confirmed that the NSE letter is enclosed with the filing, while the BSE letter requires rectification of factual errors before being formally intimated.
Conditions for listing
The exchanges have stipulated several conditions that Krsnaa Diagnostics must fulfill before the final listing of the shares. These include filing the listing application promptly after allotment and securing all necessary statutory approvals from authorities such as SEBI, RBI, and the Ministry of Corporate Affairs.
Internal control mandates
NSE specifically advised the company to strengthen internal controls to monitor trades executed by the proposed allottees. This measure aims to prevent non-compliance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations. Key directives include:
- Obtaining an undertaking from allottees confirming they will not engage in intra-day trading or sell shares until the allotment date.
- Verifying compliance with Regulation 167(6) of SEBI ICDR Regulations, 2018, which places the responsibility solely on the issuer.
- Noting that any observed non-compliance post-verification may impact the listing of such shares.
Regulatory context
The in-principle approval is subject to the company’s continued compliance with all applicable guidelines, regulations, and directions of the exchanges and statutory authorities as of the date of the listing application. The exchanges reserve the right to withdraw approval if submitted information is found to be incomplete, incorrect, or misleading.
Historical Stock Returns for Krsnaa Diagnostics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.95% | -5.00% | -5.69% | -6.49% | -34.59% | -32.40% |
How will the dilution from converting 16.21 lakh warrants at ₹566 impact Krsnaa Diagnostics' existing shareholder value and EPS in the upcoming quarters?
What specific capital deployment strategies has the promoter group outlined for the funds raised through this preferential warrant issuance?
Will the requirement to rectify factual errors in the BSE letter cause significant delays in the final allotment and listing timeline?































